NCT00211497View on ClinicalTrials.gov

Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne

PHASE2CompletedINTERVENTIONAL
Enrollment

255

Participants

Timeline

Start Date

January 31, 2003

Study Completion Date

September 30, 2003

Conditions
Acne VulgarisAcnePropionibacterium Acnes
Interventions
DRUG

MBI 226 Acne Solutions

Sponsors
All Listed Sponsors
lead

BioWest Therapeutics Inc

INDUSTRY